Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics (NASDAQ: ORKA), a clinical-stage biotech company, has reported significant progress in its Q2 2025 pipeline development for chronic skin disease treatments. The company has initiated the EVERLAST-A Phase 2a trial for ORKA-001, their novel IL-23p19 antibody, with first patients dosed and data expected in 2H 2026.
Key financial metrics show a strong position with $351.5 million in cash and equivalents. R&D expenses increased to $24.1 million from $18.7 million year-over-year, while net loss widened to $24.6 million. The company is advancing multiple programs, including ORKA-002 (IL-17A/F antibody) in Phase 1 trials, with data expected around YE 2025, and the development of ORKA-021, a sequential combination therapy.
Oruka Therapeutics (NASDAQ: ORKA), azienda biotech in fase clinica, ha riportato progressi significativi nella pipeline del 2° trimestre 2025 per terapie delle malattie cutanee croniche. La società ha avviato lo studio EVERLAST-A di Fase 2a per ORKA-001, il nuovo anticorpo anti‑IL‑23p19, con i primi pazienti già dosati e dati previsti nella 2ª metà del 2026.
La posizione finanziaria è solida con $351.5 milioni in cassa e mezzi equivalenti. Le spese di R&S sono salite a $24.1 milioni rispetto a $18.7 milioni anno su anno, mentre la perdita netta si è ampliata a $24.6 milioni. L’azienda avanza più programmi, tra cui ORKA‑002 (anticorpo IL‑17A/F) in Fase 1 con dati attesi verso la fine del 2025, e lo sviluppo di ORKA‑021, una terapia combinata sequenziale.
Oruka Therapeutics (NASDAQ: ORKA), compañía biotecnológica en fase clínica, informó avances importantes en su desarrollo de pipeline en el 2T 2025 para tratamientos de enfermedades cutáneas crónicas. La empresa ha iniciado el ensayo EVERLAST‑A de Fase 2a para ORKA‑001, su nuevo anticuerpo contra IL‑23p19, con los primeros pacientes dosificados y datos esperados en la 2ª mitad de 2026.
Las métricas financieras muestran una posición sólida con $351.5 millones en efectivo y equivalentes. Los gastos de I+D aumentaron a $24.1 millones desde $18.7 millones interanual, mientras que la pérdida neta se amplió a $24.6 millones. La compañía avanza múltiples programas, incluido ORKA‑002 (anticuerpo IL‑17A/F) en ensayos de Fase 1 con datos esperados hacia finales de 2025, y el desarrollo de ORKA‑021, una terapia combinada secuencial.
Oruka Therapeutics (NASDAQ: ORKA), 임상 단계의 바이오텍 기업이 만성 피부질환 치료제 파이프라인에서 2025년 2분기에 의미 있는 진전을 보고했습니다. 회사는 새로운 IL‑23p19 항체 ORKA‑001에 대한 EVERLAST‑A 2a상 시험을 시작했으며 첫 환자 투여가 이루어졌고 데이터는 2026년 하반기에 예상됩니다.
재무 지표는 $351.5백만의 현금 및 현금성 자산으로 견조한 상황을 보여줍니다. 연구개발비는 전년 대비 $18.7백만에서 $24.1백만으로 증가했으며, 당기 순손실은 $24.6백만으로 확대되었습니다. 회사는 ORKA‑002(IL‑17A/F 항체) 등 다수의 프로그램을 진행 중이며, 해당 제품은 1상으로 연말(2025년경) 데이터가 기대되며 ORKA‑021이라는 순차적 병용요법 개발도 진행하고 있습니다.
Oruka Therapeutics (NASDAQ: ORKA), société biotech en phase clinique, a annoncé des progrès significatifs de sa pipeline au T2 2025 pour les traitements des maladies cutanées chroniques. La société a lancé l'essai EVERLAST‑A de Phase 2a pour ORKA‑001, son nouvel anticorps anti‑IL‑23p19, avec les premiers patients traités et des données attendues au second semestre 2026.
Les indicateurs financiers montrent une position solide avec 351,5 millions de dollars en liquidités et équivalents. Les dépenses de R&D ont augmenté à 24,1 millions de dollars contre 18,7 millions l’année précédente, tandis que la perte nette s’est élargie à 24,6 millions de dollars. La société fait progresser plusieurs programmes, dont ORKA‑002 (anticorps IL‑17A/F) en phase 1 avec des données attendues vers la fin 2025, et le développement d’ORKA‑021, une thérapie combinée séquentielle.
Oruka Therapeutics (NASDAQ: ORKA), ein Biotech-Unternehmen in klinischer Phase, meldet bedeutende Fortschritte in seiner Pipeline für chronische Hauterkrankungen im 2. Quartal 2025. Das Unternehmen hat die EVERLAST‑A Phase‑2a‑Studie für ORKA‑001, einen neuartigen IL‑23p19‑Antikörper, gestartet; die ersten Patienten wurden dosiert und Daten werden in der 2. Hälfte 2026 erwartet.
Die Finanzkennzahlen zeigen eine solide Lage mit $351.5 Millionen an liquiden Mitteln und Äquivalenten. Die F&E‑Ausgaben stiegen von $18.7 Millionen auf $24.1 Millionen im Jahresvergleich, während der Nettoverlust auf $24.6 Millionen anwuchs. Das Unternehmen treibt mehrere Programme voran, darunter ORKA‑002 (IL‑17A/F‑Antikörper) in Phase 1 mit Daten gegen Ende 2025 erwartet, sowie die Entwicklung von ORKA‑021 als sequentielle Kombinationstherapie.
- Strong cash position of $351.5 million provides runway for clinical development
- EVERLAST-A Phase 2a trial successfully initiated with first patients dosed
- Multiple pipeline programs advancing simultaneously (ORKA-001, ORKA-002, ORKA-021)
- Potential for yearly dosing and extended off-treatment remissions in ORKA-001 program
- Increased net loss to $24.6 million from $22.2 million year-over-year
- Higher R&D expenses at $24.1 million, up from $18.7 million in Q2 2024
- Key clinical data readouts not expected until 2H 2026 for main program
Insights
Oruka advances IL-23 inhibitor in psoriasis with promising trial design targeting extended dosing and off-treatment remission potential.
Oruka Therapeutics is making significant progress with its psoriasis pipeline, most notably with the advancement of ORKA-001, their novel half-life extended IL-23p19 monoclonal antibody. The initiation of the EVERLAST-A Phase 2a trial represents a crucial milestone, with first patients already dosed and most sites expected to be enrolling by month-end. This 80-patient study has a thoughtfully designed protocol with a primary endpoint of PASI 100 (complete skin clearance) at Week 16, followed by an innovative randomization at Week 28 to evaluate extended dosing intervals.
What's particularly noteworthy about EVERLAST-A's design is the inclusion of a "no-dose" arm, where patients who achieve complete clearance won't receive additional treatment until disease recurrence. This directly tests two key potential differentiators: the possibility of yearly dosing intervals and the potential for extended off-treatment remissions - both representing significant advantages over current standards of care in psoriasis.
The company's pipeline depth is also impressive, with ORKA-002 (IL-17A/F inhibitor) in Phase 1 and plans for data around year-end 2025. Their sequential combination therapy approach (ORKA-021) combining both mechanisms could potentially deliver superior efficacy with an optimized maintenance profile. With
The psoriasis market continues to reward innovation, particularly for biologics that can demonstrate superior efficacy, convenience, or safety profiles. If ORKA-001 can deliver on its promise of ultra-long dosing intervals while maintaining high efficacy, it could capture significant market share in this competitive but lucrative therapeutic area.
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026
ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025
ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025
MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported second quarter 2025 financial results and provided a corporate update.
“We are very pleased to have initiated our EVERLAST-A study, and we expect nearly all our sites to be open and enrolling by the end of the month,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “This study could demonstrate three different aspects of ORKA-001’s differentiation – an ultra-long dosing interval, higher efficacy than other IL-23 inhibitors, and the potential for off-treatment remissions. Together with our ORKA-002 program and ORKA-021 sequential combination that are following close behind, we are confident we can have the best biologic regimens in psoriatic disease, an area that continues to reward innovation in biologics.”
Second Quarter Business and Pipeline Updates
ORKA-001: a novel half-life extended IL-23p19 monoclonal antibody
- Enrollment is ongoing in EVERLAST-A following clearance from both the U.S. FDA and Health Canada in July, and the first patients have been dosed in the study. EVERLAST-A is a randomized, double-blind, placebo-controlled Phase 2a trial designed to enroll approximately 80 patients with moderate-to-severe plaque psoriasis. Patients will be randomized 3:1 to receive ORKA-001 or placebo with a primary endpoint of PASI 100 at Week 16. At Week 28, patients who have achieved PASI 100, or completely clear skin, will be randomized 2:1 to either (1) an arm where they do not receive another dose until disease recurs or (2) ORKA-001 every six months. This “no-dose” arm will provide evidence for both yearly dosing and the potential for extended off-treatment remissions. Additional details on the EVERLAST-A design will be presented at the European Academy of Dermatology and Venereology (EADV) Congress in September. The Company expects to share efficacy and response duration data from EVERLAST-A in 2H 2026. Psoriasis trials historically have low placebo rates and high reproducibility across phases of development, making this Phase 2a readout particularly impactful for demonstrating ORKA-001’s differentiation.
- Oruka’s Phase 1 trial of ORKA-001 is ongoing, with dosing completed for all 24 subjects across three dose levels. The trial is a double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of ORKA-001. The Company will present data from this trial at EADV in September.
ORKA-002: a novel half-life extended IL-17A/F monoclonal antibody
- The first participants were dosed in a Phase 1 trial of ORKA-002 in May, and the trial is ongoing. The trial is a double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, and PK of ORKA-002 in approximately 24 healthy volunteers. The Company expects to share interim data from this trial, including initial PK data, around YE 2025, and to initiate a Phase 2 trial in psoriasis in 1H 2026.
Additional programs and updates
- Laura Sandler, who joined Oruka in 2024 as SVP of Operations, was promoted to Chief Operating Officer.
- ORKA-021 (ORKA-002 → ORKA-001): Oruka continues to advance a sequential combination regimen of ORKA-002 and ORKA-001, which could deliver rapid and deep responses with an ideal maintenance profile. ORKA-021 could create another opportunity for the Company to define the best possible regimen for the treatment of psoriatic disease.
- ORKA-003: The Company continues to progress ORKA-003 through preclinical development.
Second Quarter 2025 Financial Results
Cash Position: As of June 30, 2025, Oruka had available cash, cash equivalents, and marketable securities of
Research and Development (R&D) expenses: R&D expenses totaled
General and Administrative (G&A) expenses: G&A expenses totaled
Other income (expense), net: Other income, net for the second quarter of 2025 was
Net loss: Net loss totaled
Shares Outstanding: Oruka has approximately 55.1 million shares of the Company’s common stock and common stock equivalents issued and outstanding, including shares of common stock underlying pre-funded warrants and non-voting convertible preferred stock.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Forward Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Oruka’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Oruka’s ability to achieve the expected benefits or opportunities with respect to ORKA-001, ORKA-002 and ORKA-021, including timelines to clinical and data release milestones, trial and site initiation timelines, and the details of its planned clinical studies, as well as the potential exposures and dosing interval of ORKA-001. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and its registration statement on Form S-1. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
| ORUKA THERAPEUTICS, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (unaudited) | |||||||
| (in thousands) | |||||||
| June 30, | December 31, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 65,396 | $ | 61,575 | |||
| Marketable securities, current | 263,010 | 314,073 | |||||
| Prepaid expenses and other current assets | 3,606 | 1,221 | |||||
| Total current assets | 332,012 | 376,869 | |||||
| Marketable securities, long-term | 23,053 | 18,069 | |||||
| Property and equipment, net | 174 | 162 | |||||
| Operating lease right-of-use assets | 2,076 | 876 | |||||
| Other non-current assets | 103 | 43 | |||||
| Total assets | $ | 357,418 | $ | 396,019 | |||
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 4,664 | $ | 3,462 | |||
| Accrued expenses and other current liabilities | 3,578 | 3,346 | |||||
| Operating lease liability, current | 660 | 213 | |||||
| Related party common stock warrant liability | 3,089 | — | |||||
| Related party accounts payable and other current liabilities | 119 | 6,022 | |||||
| Total current liabilities | 12,110 | 13,043 | |||||
| Operating lease liability, non-current | 1,666 | 755 | |||||
| Total liabilities | 13,776 | 13,798 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Series B non-voting convertible preferred stock | 2,931 | 2,931 | |||||
| Common stock | 37 | 37 | |||||
| Additional paid-in capital | 469,998 | 463,018 | |||||
| Accumulated other comprehensive loss | (27 | ) | (41 | ) | |||
| Accumulated deficit | (129,297 | ) | (83,724 | ) | |||
| Total stockholders’ equity | 343,642 | 382,221 | |||||
| Total liabilities, convertible preferred stock and stockholders’ equity | $ | 357,418 | $ | 396,019 | |||
| ORUKA THERAPEUTICS, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||
| (unaudited) | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Period from February 6, 2024 (Inception) to June 30, 2024 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development(1) | $ | 24,087 | $ | 18,673 | $ | 44,012 | $ | 23,866 | |||||||
| General and administrative(1) | 4,342 | 2,820 | 9,503 | 4,490 | |||||||||||
| Total operating expenses | 28,429 | 21,493 | 53,515 | 28,356 | |||||||||||
| Loss from operations | (28,429 | ) | (21,493 | ) | (53,515 | ) | (28,356 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 3,857 | — | 7,949 | — | |||||||||||
| Interest expense | — | (750 | ) | — | (964 | ) | |||||||||
| Other expense, net | (2 | ) | — | (7 | ) | — | |||||||||
| Total other income (expense), net | 3,855 | (750 | ) | 7,942 | (964 | ) | |||||||||
| Net Loss | (24,574 | ) | (22,243 | ) | (45,573 | ) | (29,320 | ) | |||||||
| Net change in unrealized gains (losses) on marketable securities | (21 | ) | — | 14 | — | ||||||||||
| Comprehensive loss | $ | (24,595 | ) | $ | (22,243 | ) | $ | (45,559 | ) | $ | (29,320 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.46 | ) | $ | (6.96 | ) | $ | (0.85 | ) | $ | (9.17 | ) | |||
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $ | (38.26 | ) | $ | — | $ | (71.23 | ) | $ | — | |||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 42,095,951 | 3,197,975 | 41,888,906 | 3,197,975 | |||||||||||
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 137,138 | — | 137,138 | — | |||||||||||
| (1) Amounts include non-cash stock based compensation expense as follows (in thousands): | |||||||||||||||
| Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Period from February 6, 2024 (Inception) to June 30, 2024 | ||||||||||||
| Research and development | $ | 3,368 | $ | 468 | $ | 6,371 | $ | 538 | |||||||
| General and administrative | 1,709 | 215 | 3,589 | 230 | |||||||||||
| Total | $ | 5,077 | $ | 683 | $ | 9,960 | $ | 768 | |||||||
FAQ
When will Oruka Therapeutics (ORKA) report EVERLAST-A Phase 2a trial results?
What is the cash position of Oruka Therapeutics (ORKA) as of Q2 2025?
What are the main programs in Oruka Therapeutics' pipeline?
How much did Oruka Therapeutics (ORKA) spend on R&D in Q2 2025?
What is the EVERLAST-A trial design for ORKA-001?
